176 related articles for article (PubMed ID: 33556161)
1. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK
Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib.
Banasavadi-Siddegowda YK; Namagiri S; Otani Y; Sur H; Rivas S; Bryant JP; Shellbourn A; Rock M; Chowdhury A; Lewis CT; Shimizu T; Walbridge S; Kumarasamy S; Shah AH; Lee TJ; Maric D; Yan Y; Yoo JY; Kumbar SG; Heiss JD; Kaur B
Neurooncol Adv; 2022; 4(1):vdac095. PubMed ID: 35875691
[TBL] [Abstract][Full Text] [Related]
3. Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
Gordon IK; Lu J; Graves CA; Huntoon K; Frerich JM; Hanson RH; Wang X; Hong CS; Ho W; Feldman MJ; Ikejiri B; Bisht K; Chen XS; Tandle A; Yang C; Arscott WT; Ye D; Heiss JD; Lonser RR; Camphausen K; Zhuang Z
Mol Cancer Ther; 2015 Jul; 14(7):1540-1547. PubMed ID: 25939762
[TBL] [Abstract][Full Text] [Related]
4. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Banasavadi-Siddegowda YK; Russell L; Frair E; Karkhanis VA; Relation T; Yoo JY; Zhang J; Sif S; Imitola J; Baiocchi R; Kaur B
Oncogene; 2017 Jan; 36(2):263-274. PubMed ID: 27292259
[TBL] [Abstract][Full Text] [Related]
5. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
Hao S; Song H; Zhang W; Seldomridge A; Jung J; Giles AJ; Hutchinson MK; Cao X; Colwell N; Lita A; Larion M; Maric D; Abu-Asab M; Quezado M; Kramp T; Camphausen K; Zhuang Z; Gilbert MR; Park DM
Neuro Oncol; 2018 May; 20(6):799-809. PubMed ID: 29294092
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Liu L; Wang H; Cui J; Zhang Q; Zhang W; Xu W; Lu H; Liu S; Shen S; Fang F; Li L; Yang W; Zhuang Z; Li J
Cell Physiol Biochem; 2018; 50(1):317-331. PubMed ID: 30282066
[TBL] [Abstract][Full Text] [Related]
7. PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B
Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation.
Gao S; Shan L; Zhang M; Wang Y; Zhan X; Yin Y; Jiang Z; Tao X; Li X; Ye M; Liu Y
Cell Oncol (Dordr); 2022 Dec; 45(6):1203-1215. PubMed ID: 36136269
[TBL] [Abstract][Full Text] [Related]
9. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells.
Ho WS; Feldman MJ; Maric D; Amable L; Hall MD; Feldman GM; Ray-Chaudhury A; Lizak MJ; Vera JC; Robison RA; Zhuang Z; Heiss JD
Oncotarget; 2016 Mar; 7(11):12447-63. PubMed ID: 26799670
[TBL] [Abstract][Full Text] [Related]
10. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
Chang KE; Wei BR; Madigan JP; Hall MD; Simpson RM; Zhuang Z; Gottesman MM
Mol Cancer Ther; 2015 Jan; 14(1):90-100. PubMed ID: 25376608
[TBL] [Abstract][Full Text] [Related]
11. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.
Wei D; Parsels LA; Karnak D; Davis MA; Parsels JD; Marsh AC; Zhao L; Maybaum J; Lawrence TS; Sun Y; Morgan MA
Clin Cancer Res; 2013 Aug; 19(16):4422-32. PubMed ID: 23780887
[TBL] [Abstract][Full Text] [Related]
13. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB
Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912
[TBL] [Abstract][Full Text] [Related]
14. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
[TBL] [Abstract][Full Text] [Related]
15. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
16. LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.
Hong CS; Ho W; Zhang C; Yang C; Elder JB; Zhuang Z
Cancer Biol Ther; 2015; 16(6):821-33. PubMed ID: 25897893
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
Zhang C; Hong CS; Hu X; Yang C; Wang H; Zhu D; Moon S; Dmitriev P; Lu J; Chiang J; Zhuang Z; Zhou Y
Cell Cycle; 2015; 14(13):2100-8. PubMed ID: 25942376
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
Maggio D; Ho WS; Breese R; Walbridge S; Wang H; Cui J; Heiss JD; Gilbert MR; Kovach JS; Lu RO; Zhuang Z
J Neurooncol; 2020 Jun; 148(2):231-244. PubMed ID: 32342332
[TBL] [Abstract][Full Text] [Related]
19. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Mirzapoiazova T; Xiao G; Mambetsariev B; Nasser MW; Miaou E; Singhal SS; Srivastava S; Mambetsariev I; Nelson MS; Nam A; Behal A; Arvanitis LD; Atri P; Muschen M; Tissot FLH; Miser J; Kovach JS; Sattler M; Batra SK; Kulkarni P; Salgia R
Mol Cancer Ther; 2021 Oct; 20(10):1820-1835. PubMed ID: 34253596
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
Lv P; Wang Y; Ma J; Wang Z; Li JL; Hong CS; Zhuang Z; Zeng YX
Oncotarget; 2014 Sep; 5(17):7512-24. PubMed ID: 25245035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
